3rd Quarter Financial Results for FYE 3/2007 (Consolidated)
Name of listed company: TERUMO CORPORATION( URL http://www.terumo.com/ )Company code number: 4543
Representative:
Akira Takahashi, President
Please address all communications to:
Kunio Kimishima, General Manager, Corporate Communication Dept.

January 29, 2007

Exchange where listed: TSE
Location of headquarters (prefecture): Tokyo

Phone: +81 / 3-3217 - 6550

1. Consolidated Financial Highlights for the nine months ended December 2006 - Unaudited(From April 1, 2006 to December 31, 2006)(1) Consolidated financial results(Note: The amounts shown below ignore values of less than a million yen)
Net sales

Operating income(Millions of yen)

Nine months ended December, 2006
Nine months ended December, 2005
Year ended March, 2006

% (Millions of yen)

205,148
183,593
247,048

11.7
7.0

Net income per share

Ordinary income% (Millions of yen)

45,22838,701
48,251

16.9
7.0

Net income% (Millions of yen)

46,25439,30348,934

17.7
8.8

%

29,54325,04732,45718.0
13.6

Net income per share,
fully diluted(Yen)(Yen)

Nine months ended December, 2006
146.20Nine months ended December, 2005
124.65
Year ended March, 2006
160.45* The percentages shown next to net sales, operating income, ordinary income and net income represent year-on-year changes.
(2) Consolidated financial position
Total assets
December 31, 2006
December 31, 2005
March 31, 2006

(Millions of yen)

(Millions of yen)

356,615
347,003354,648

279,830
265,966
273,309(3) Consolidated statements of cash flows
Cash flows fromoperating activities
Nine months ended December, 2006
Nine months ended December, 2005
Year ended March, 2006

Net assetsCash flows frominvesting activities

Capital asset ratio

Net assets per share%

78.5
76.7
77.1
Cash flows fromfinancing activities(Yen)

1,407.38
1,309.99
1,345.52
Cash and cash equivalents,end of the period(Millions of yen)

(Millions of yen)

(Millions of yen)

(Millions of yen)

28,83923,23643,380(12,427)(25,283)(54,391)(28,365)
2,258
370

36,69558,58847,963(4) Changes in scope of consolidation and in application of the equity method
Consolidation (new) :2(elimination): None
Equity method (new) :None(elimination): None
(5) All financial results for the consolidated financial period from April 1, 2006 to December 31, 2006 are not audited
by independent auditors.

2. Consolidated forecasts for the year ending March 2007 (From April 1, 2006 to March 31, 2007)
Net sales(Millions of yen)

Operating income(Millions of yen)

Ordinary income(Millions of yen)

Net income(Millions of yen)

Year ended March, 2007
273,000
57,50057,50037,000(N.B.) Estimated net income per share (full year): 186.13 yen(Computing basis: the balance of shares as of the end of this 3rd quarter after deduction of Treasury stock)
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual
results, performance or achievements to differ materially from that anticipated in these statements.

3. Consolidated Financial Statements(1) Consolidated Balance Sheet

Current Assets
Cash and cash equivalents
Trade receivable notes/accounts
Inventories
Other current assets
Fixed Assets
Tangible fixed assets
Building and structures
Machinery and transportation equipment
LandConstruction in progress
Other tangible assets
Intangible fixed assets
Investments and other assets
Investment in securities
Other investments and other assets
Total Assets

December 31, 2005
Amount%174,832
50.4
58,58865,11039,595
11,537
172,17149.6
108,31331.2
42,931
28,222
20,369
9,159
7,629
21,674
6.2
42,183
12.2
35,9196,264
347,003
100.0

Current Liabilities
Trade payable notes/accounts
Short-term bank loans
Other current liabilities
Long-term Liabilities
Long-term bank loans
Reserve for retirement allowance
Other long-term liabilities
Total Liabilities
Minority Interests
Common stock
Capital surplus
Retained earningsTreasury stock
Total Stockholders' Equity
Other Securities Valuation Difference
Gain / Loss on deferred hedge
Translation Adjustments
Total Valuation and Translation Adjustments
Minority Interests
Total Net Assets

59,42023,3705,858
30,191
21,56819,3552,212
80,98848-

Total Liabilities and Net Assets

-

17.1

December 31, 2006
Amount%163,283
45.8
36,93570,244
44,211
11,891
193,332
54.2
114,864
32.2
44,94430,572
20,30011,718
7,328
41,116
11.5
37,35010.5
33,173
4,177
356,615
100.0

23.3
0.0
-

61,891
24,081476
37,33314,893
440
11,361
3,091
76,78538,71659,030207,524(33,443)
271,828
7,983
(2)
(36)
7,945
56
279,830-

356,615

6.2

17.3(Millions of yen)March 31, 2006
Amount%165,486
46.7
47,96363,02440,941
13,556
189,16153.3
109,837
31.0
42,591
28,401
20,384
10,697
7,762
41,972
11.8
37,351
10.5
32,162
5,188
354,648
100.0

21.5
10.9
16.6
58.2
(9.4)
76.3
2.2
(0.0)
(0.0)
2.2
0.0
78.5

66,87623,8583,975
39,043
14,412
12,171
2,240
81,28849-

22.90.0-

100.0-

-

4.2

18.9

4.0

Common stock
Capital surplus
Retained earnings
Other Securities Valuation Difference
Translation Adjustments
Treasury stock
Total Stockholders' Equity

38,71659,030175,981
8,370(2,690)(13,442)
265,966

11.2
17.0
50.7
2.4
(0.8)
(3.8)
76.7

-

-

38,71659,030183,391
7,367(1,747)(13,449)
273,309

10.9
16.6
51.7
2.1
(0.4)
(3.8)
77.1

Total Liabilities, Minority Interests and Stockholders' Equity

347,003100.0--

354,648100.0

(2) Consolidated Statement of Income

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income / expenses
Ordinary income
Extraordinary income / expenses
Income before taxes
Corporate, inhabitant and enterprise taxes
Net income for the period

Nine months ended
December 31, 2005
Amount%183,593
100.0
83,47545.5
100,118
54.5
61,41733.4
38,70121.1
602
39,303
21.4(1,106)38,19620.8
13,14925,047
13.6

Nine months ended
December 31, 2006
Amount%205,148
100.0
91,94344.8
113,205
55.2
67,97633.2
45,22822.0
1,025
46,25422.5(773)
45,48022.2
15,93629,543
14.4(Millions of yen)
Year ended
March 31, 2006
Amount%247,048100.0
111,37745.1
135,67054.9
87,41935.4
48,251
19.5
683
48,93419.8
2,653
51,58820.9
19,13132,457
13.1

Nine months ended
December 31, 2005
23,236(25,283)
2,258
819
1,030
57,55758,588Nine months ended
December 31, 2006
28,839(12,427)(28,365)684(11,268)
47,96336,695(Millions of yen)
Year ended
March 31, 2006
43,380(54,391)370
1,046(9,594)57,55747,963

December 31, 2005
183,416

December 31, 2006
195,329(Millions of yen)March 31, 2006
186,091

Nine months ended
December 31, 2005
11,124

Nine months ended
December 31, 2006
11,608(Millions of yen)
Year ended
March 31, 2006
18,024

Nine months ended
December 31, 2005
65
54
156

Nine months ended
December 31, 2006
43-(Millions of yen)
Year ended
March 31, 2006
71
4,966
25
156

536
3
190
59592
-

75
12728

(3) Consolidated Statement of Cash Flows

Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Effect of exchange rate changes on cash and cash equivalents
Change in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of period(4)Notes
Relating to balance sheet

Accumulated depreciation of tangible assets

Relating to statement of income
Main items among selling, general and administrative expenses

R&D expenditure
Main items among extraordinary income / expenses

Gain on sales of property, plant and equipment
Gain on contribution of securities to retirement benefit trust
Gain on reversal of allowance for bad debts
Gain on sales of trade receivables written off
Loss on disposal of property, plant and equipment
Loss on sales and impairment of golf memberships
Loss on restructuring in subsidiaries
Loss on restructuring in overseas operation
Compensation for retired directors
Expense for acquisition of newly consolidated subsidiary
Impairment loss on property, plant and equipment
Provision for retirement benefits for directors and corporate auditors

661
6196
575
59473
592-4. Segment Information(1) Sales results by product segment(Millions of yen)
Nine months ended Nine months ended
December 31, 2005 December 31, 2006
Amount%Amount%Disposable medical equipment
Pharmaceuticals
Blood transfusion systems
General hospital products
Catheter systems
Cardiovascular systems
Vascular grafts
Cardiac & Vascular products
CAPD systems
Diabetes care products
Other productsHome health care products
TotalChanges
Amount%57,23931.2%

59,096

28.8%

1,856

27,37414.9%

29,756

14.5%

2,381

8.7%

12,563

6.8%

14,217

6.9%

1,653

13.2%

97,17852.9%

103,069

50.2%

5,891

6.1%

36,63820.0%

46,531

22.7%

9,892

27.0%23,281

12.7%

26,485

12.9%

3,203

13.8%

5,189

2.8%

7,207

3.5%

2,017

38.9%

65,10935.5%

80,22339.1%

15,114

23.2%

5,977

3.2%

5,510

2.7%

(467)

(7.8%)

7,467

4.1%

9,395

4.6%

1,928

25.8%

7,861

4.3%

6,949

3.4%

(911)

(11.6%)

21,855
10.7%
205,148 100.0%

549
21,554

2.6%
11.7%

21,306
11.6%
183,593 100.0%

3.2%

Note 1) Main Products belonging to each product segment
Product segment

Main Products

Disposable medical equipment

Syringes, Needles, Solution Administration sets, I.V.catheters,
Blood collection tubes, Electronic medical devices, etc.
I.V.solution, Prefilled syringes, Nutritional products, etc.
Blood bags, medical electronic devices for blood collection, etc.
PTCA dilation catheters, Coronary stents, Guide wires,
Angiographic catheters, Cerebral aneurysm coils, etc.
Roller pumps, Hollow fiber oxygenators, Blood circuits, etc.
Artificial vascular grafts
Dialysis solution, etc.
Blood glucose monitors, etc.
Home oxygen systems, Home nutritional products, Digital
Thermometers, Electronic sphygmomanometers, etc.

Pharmaceuticals
Blood transfusion systems
Catheter systems
Cardiovascular systems
Vascular grafts
CAPD systems
Diabetes care products
Other products(2) Sales results by region(Millions of yen)
Nine months ended Nine months ended
December 31, 2005 December 31, 2006
Amount%Amount%Japan
EuropeAmerica
Asia and Others
Total

ChangesAmount%112,28461.2%

115,275

56.2%

2,990

2.7%

28,18915.3%

34,771

17.0%

6,581

23.3%

28,50515.5%

38,029

18.5%

9,524

33.4%

17,072
8.3%
205,148 100.0%

2,457
21,554

16.8%
11.7%

14,6148.0%
183,593 100.0%